Targeting colon cancer by TM: The studies suggest that TM could be an anti-CRC drug, as TM treatment efficiently inhibits CRC cell growth and aggressive behavior by downregulating vimentin, FIB, Ecacollagen type I, Slug expression levels, and survival of tumor-bearing mice [49]. Here, VIM is linked to colorectal carcinoma.